Skip to main content
. 2023 Apr 5;9(4):371–386. doi: 10.1093/ehjcvp/pvad025

Table 2.

Multi-system phenotyping: serial electrocardiography, biomarkers of inflammation, metabolism, renal function, haemostasis, and heart, lung, and kidney imaging at 28–60 days post-discharge

All Control COVID-19 P-value
Electrocardiogram
Myopericarditis criteria
Admission N = 37 N = 10 N = 27
7 (19%) 0 (0%) 7 (26%) 0.155
Enrolment N = 36 N = 10 N = 26
7 (19%) 0 (0%) 7 (27%) 0.155
28–60 days post-discharge N = 35 N = 10 N = 25
2 (6%) 0 (0%) 2 (8%) 1.000
CT chest 28–60 days post-discharge
N = 35 N = 9 N = 26
Ground glass opacity and/or consolidation 15 (43%) 0 (0%) 15 (58%) 0.004
Reticulation and/or architectural distortion 11 (31%) 0 (0%) 11 (42%) 0.033
Atelectasis 3 (9%) 0 (0%) 3 (12%) 0.553
Pulmonary arterial thrombus 1 (3%) 0 (0%) 1 (4%) 1.000
Visual estimate of % of total lung area abnormal 16.4 ± 23.9 0.0 ± 0.0 22.0 ± 25.4 0.015
CT coronary angiogram 28–60 days post-discharge
N = 35 N = 9 N = 26
Coronary calcium—Agatston score 52 ± 102 16 ± 47 65 ± 114 0.224
MESA percentile 63.9 ± 25.1 41.0 ±- 65.5 ± 25.2 0.365
Obstructive coronary artery disease 4 (12%) 0 (0%) 4 (16%) 0.554
FFRCT patient-level (all coronary arteries) 28–60 days post-discharge
N = 33 N = 9 N = 24
Median FFRCT 0.92 ± 0.04 0.94 ± 0.01 0.92 ± 0.04 0.133
Minimum FFRCT ≤ 0.8 11 (33%) 1 (11%) 10 (42%) 0.212
Cardiac MRI 28–60 days post-discharge
N = 34 N = 9 N = 25
LV end diastolic volume index, mL/m2 74.0 ± 14.1 79.1 ± 14.2 72.2 ± 13.9 0.209
LV end systolic volume index, mL/m2 31.5 ± 9.8 31.1 ± 9.8 31.7 ± 10.0 0.891
LV ejection fraction, % 58.0 ± 7.7 61.2 ± 6.4 56.9 ± 7.9 0.153
LV mass, g 103.4 ± 29.9 124.8 ± 25.5 95.7 ± 27.9 0.010
RV end diastolic volume index, mL/m2 73.3 ± 15.6 85.7 ± 10.4 68.6 ± 14.7 0.003
RV end systolic volume index, mL/m2 31.7 ± 8.2 34.3 ± 5.6 30.8 ± 8.9 0.285
RV ejection fraction, % 55.8 ± 9.9 59.9 ± 5.6 54.3 ± 10.7 0.150
Myocardial tissue characterization
N = 34 N = 9 N = 25
Increased global T1 (>1233 ms) 9 (26%) 2 (22%) 7 (28%) 1.000
Increased global T2 (>44 ms) 0 (0%) 0 (0%) 0 (0%) 1.000
T2 ratio (myocardium/serratus anterior muscle) 1.68 ± 0.22 1.64 ± 0.12 1.70 ± 0.25 0.561
Increased global extracellular volume (>27.4%) 15 (44%) 1 (11%) 14 (56%) 0.047
Late gadolinium enhancement
N = 35 N = 10 N = 25
Myocardial late gadolinium enhancement 3 (9%) 0 (0%) 3 (12%) 0.549
Ischaemic distribution 1 (3%) 0 (0%) 1 (4%) 1.000
Non-ischaemic distribution 2 (6%) 0 (0%) 2 (8%) 1.000
Myocardial inflammation (Lake Louise criteria)
No evidence (0/2) 13 (37%) 10 (100%) 3 (12%) 0.001
Probable (1/2) 10 (29%) 0 (0%) 10 (40%)
Definite (2/2) 12 (34%) 0 (0%) 12 (48%)
Renal MRI
N = 35 N = 10 N = 25
Average volume of right and left kidneys, mL 159 ± 35 173 ± 32 154 ± 35 0.141
Average cortex T1 of right and left kidneys, ms 1541 ± 71 1507 ± 68 1555 ± 68 0.073
Average medulla T1 of right and left kidneys, ms 1967 ± 74 1974 ± 70 1964 ± 77 0.747
Average T1 corticomedullary differentiation of kidneys 0.78 ± 0.03 0.76 ± 0.02 0.79 ± 0.02 0.004
Biomarkers at enrolment, central laboratory
N = 36 N = 10 N = 26
eGFR, mL/min/1.73 m2 95 (81, 102) 95 (91, 101) 93 (81, 103) 0.891
C-reactive protein, mg/L 2.8 (1.1, 5.8) 1.4 (0.9, 3.6) 3.2 (1.3, 6.7) 0.120
NT pro BNP, ng/L 80 (45, 163) 65 (42, 81) 140 (73, 219) 0.068
Total bilirubin, μmol/L 5.4 (4.1, 8.6) 10.4 (8.5, 12.6) 4.9 (3.7, 6.4) 0.003
Total cholesterol, mmol/L 5.30 ± 1.34 4.93 ± 0.97 5.44 ± 1.44 0.317
Triglycerides, mmol/L 2.68 ± 1.77 1.83 ± 1.29 3.01 ± 1.85 0.074
HDL cholesterol, mmol/L 1.11 ± 0.22 1.13 ± 0.21 1.10 ± 0.22 0.659
ICAM-1, ng/mL 503 (419, 633) 410 (384, 444) 582 (495, 685) <0.001
VCAM-1, ng/mL 858 (692, 1164) 654 (636, 728) 981 (823, 1254) 0.002
Endothelin-1, pg/mL 2.2 (1.9, 2.7) 2.8 (2.1, 3.0) 2.1 (1.8, 2.3) 0.039
IL-6, pg/mL 3.9 (2.9, 5.8) 3.2 (1.8, 4.6) 4.6 (2.9, 6.4) 0.080
ST2, ng/mL 21.1 (17.0, 28.3) 20.0 (14.8, 24.0) 23.2 (18.2, 30.6) 0.165
p-selectin, ng/mL 69 (53, 86) 46 (38, 62) 70 (60, 86) 0.164
D-dimer, ng/mL 207 ± 221 107 ± 67 247 ± 249 0.090
Fibrinogen, g/L 3.69 ± 1.49 2.88 ± 1.00 4.01 ± 1.55 0.041
Factor VIII, IU/dL 160 ± 91 93 ± 44 187 ± 92 0.004
Antithrombin, IU/dL 110 ± 16 105 ± 16 112 ± 15 0.198
Protein S 95.1 ± 23.7 95.1 ± 30.2 95.1 ± 21.4 0.998
Protein C 130.1 ± 29.6 112.9 ± 26.5 136.9 ± 28.4 0.028
VWF: GP1bR 209 ± 124 114 ± 41 248 ± 126 0.003
VWF: Ag 209 ± 116 151 ± 51 233 ± 127 0.059
Biomarkers at 28–60 days post-discharge, central laboratory (control group samples from enrolment visit)
N = 37 N = 10 N = 27
eGFR, mL/min/1.73 m2 94 (80, 99) 95 (91, 101) 92 (78, 97) 0.502
C-reactive protein, mg/L 1.9 (1.1, 3.3) 1.4 (0.9, 3.6) 2.0 (1.4, 3.2) 0.698
NT proBNP, ng/L 80 (61, 115) 65 (42, 81) 84 (70, 183) 0.068
D-dimer, ng/mL 137 ± 103 107 ± 67 151 ± 115 0.265
ICAM-1, ng/mL 419 (363, 503) 410 (384, 444) 450 (362, 555) 0.400
VCAM-1, ng/mL 671 (643, 953) 654 (636, 728) 841 (652, 974) 0.183
Endothelin-1, pg/mL 2.3 (2.1, 3.0) 2. 86 (2.1, 3.0) 2.3 (2.1, 2.7) 0.327
IL-6, pg/mL 2.4 (1.8, 4.4) 3.2 (1.8, 4.6) 2.4 (1.8, 4.0) 0.845
ST2, ng/mL 20.4 (14.9, 23.3) 20.0 (14.8, 24.0) 20.4 (15.2, 23.1) 0.969
p-selectin, ng/mL 59 (50, 82) 46 (38, 62) 60 (52, 82) 0.172
Prothrombin time, s 11.1 ± 0.9 11.3 ± 0.8 11.0 ± 0.9 0.321
D-dimer, ng/mL 137 ± 103 107 ± 67 151 ± 115 0.265
Fibrinogen, g/L 3.09 ± 0.90 2.88 ± 1.00 3.19 ± 0.86 0.375
Factor VIII, IU/dL 131 ± 54 93 ± 44 147 ± 50 0.005
Antithrombin, IU/dL 111 ± 17 105 ± 16 113 ± 17 0.187
Protein S 97.4 ± 22.4 95.1 ± 30.2 98.4 ± 18.8 0.701
Protein C 120.7 ± 24.3 112.9 ± 26.5 124.1 ± 23.0 0.227
VWF: GP1bR 123 ± 48 114 ± 41 127 ± 50 0.460
VWF: Ag 153 ± 60 151 ± 51 154 ± 64 0.900

Summaries are mean ± SD, median (IQR), or N (%). P-values from t-test, Wilcoxon–Mann–Whitney test, or Fisher's exact test. All P-values are two-sided. No adjustments were made for multiple comparisons.

CMR, cardiovascular magnetic resonance; CT, computed tomography; eGFR, glomerular filtration rate; ΝΤ-proBNP, N-terminal pro-brain natriuretic peptide; eGFR (CKD-EPI), estimated glomerular filtration rate using the chronic kidney disease epidemiology (CKD-EPI equation); LV, left ventricle; MESA, multi-ethnic study of atherosclerosis; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricle; T1, longitudinal relaxation time; T2, transverse relaxation time; vWF: Ag, von Willebrand factor antigen.

aCategorical data are summarized as frequency and percentage and compared between groups using Fisher's exact tests. Continuous data are summarized as mean and standard deviation, or median, and interquartile range (IQR, defined as the upper and lower quartiles) and compared between groups using Kruskal–Wallis tests.